###
中国临床研究英文版:2024,37(3):370-374
本文二维码信息
码上扫一扫!
甲状腺癌合并乳腺癌患者的激素水平及临床病理特征
(新疆医科大学第一附属医院血管甲状腺外科,新疆 乌鲁木齐 830011)
Hormone levels and clinicopathological features in patients with thyroid cancer complicated with breast cancer
(Department of Vascular Thyroid Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China)
摘要
本文已被:浏览 316次   下载 247
Received:October 19, 2023   Published Online:March 20, 2024
中文摘要: 目的 调查甲状腺癌合并乳腺癌与单纯甲状腺癌患者的激素水平和临床病理特征,以探索这两种恶性肿瘤之间的潜在联系。方法 收集2010年1月至2022年12月新疆医科大学第一附属医院收治的82例甲状腺癌合并乳腺癌患者(合并癌组)及86例单纯甲状腺癌患者(单纯癌组)的临床资料,根据身体质量指数(BMI)是否大于24 kg/m2,将合并癌患者分为超重合并癌组(37例)和正常合并癌组(45例),单纯癌患者分为超重单纯癌组(44例)和正常单纯癌组(42例)。比较两组患者一般特征、病理特征、甲状腺激素和内分泌激素水平以及不同BMI患者间的病理特征。结果 两组患者年龄、BMI及雌激素暴露时间比较差异无统计学意义(P>0.05)。但超重合并癌组患者肿瘤直径为(0.65±0.33)cm,明显小于超重单纯癌组患者的(1.06±0.97)cm,差异有统计学意义(t=2.452, P=0.018)。合并癌组既往有生育史的比例明显高于单纯癌组(93.90% vs 80.23%, χ2=6.892, P=0.009)。与单纯癌组相比,合并癌组甲状腺素(T4)、雌三醇、孕酮水平更高,差异均有统计学意义(P<0.05)。合并癌组睾酮水平明显低于单纯癌组,差异有统计学意义[0.77(0.48,1.02) nmol/L vs 0.88(0.68,1.21) nmol/L,z=3.008, P=0.003]。结论 合并乳腺癌的甲状腺癌患者与单纯甲状腺癌患者相比,在临床生化指标上有更高的血清T4、孕酮和雌三醇以及更低的睾酮水平。虽然未发现BMI与临床病理特征之间的关联,但超重的合并癌患者其病理特征表现为肿瘤直径更小,因此临床上要加强肥胖患者健康宣教及疾病筛查。
Abstract:Objective To study the hormone levels and clinicopathological characteristics of patients with thyroid cancer and breast cancer, and to explore the possible relationship between the two cancers. Methods Clinical data of 82 cases of thyroid cancer with breast cancer (combined cancer group) patients and 86 cases of simple thyroid cancer (thyroid cancer group) patients in The First Affiliated Hospital of Xinjiang Medical University from January 2010 to December 2022 were collected. According to whether the BMI was greater than 24, patients in combined cancer group were divided into overweight combined cancer group (n=37) and normal combined cancer group (n=45), and patients in thyroid cancer group were divided into overweight thyroid cancer group (n=44) and normal thyroid cancer group (n=42). The general characteristics, pathological characteristics, thyroid hormone and endocrine hormone levels of the two groups, and pathological features of different BMI subgroups were compared. Results There was no significant difference in age, BMI and menstrual status between the two groups (P>0.05). However, the tumor diameter of patients in overweight combined cancer group was (0.65±0.33) cm, which was significantly smaller than that of patients in overweight thyroid cancer group [(1.06±0.97) cm], and the difference was statistically significant (t=2.452, P=0.018). The proportion of patients with previous reproductive history in the combined cancer group was significantly higher〖LM〗 than that in the thyroid cancer group (93.90% vs 80.23%, χ2=6.892, P=0.009). The levels of thyroxine, estriol and progesterone were higher in the combined cancer group than those in the thyroid cancer group, and the differences were statistically significant (P<0.05). The level of testosterone in the combined cancer group was significantly lower than that in the thyroid cancer group [0.77(0.48,1.02) nmol/L vs 0.88(0.68,1.21) nmol/L,z=3.008, P=0.003]. Conclusion Patients with thyroid cancer combined with breast cancer have higher serum thyroxine, progesterone and estritol and lower testosterone levels on clinical biochemical markers compared with patients with thyroid cancer alone. Although no correlation was found between BMI and clinicopathologic features, the pathological features of overweight patients with breast cancer and thyroid cancer showed smaller tumor diameter. Therefore, health education and disease screening for obese patients should be strengthened clinically.
文章编号:     中图分类号:R736.1 R737.9    文献标志码:A
基金项目:
引用文本:


Scan with WeChat

Scan with WeChat